LFMSBioMGeri: Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression

Sponsor
Mclean Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03484494
Collaborator
(none)
24
1
2
61.1
0.4

Study Details

Study Description

Brief Summary

The protocol involves functional Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy acquisitions immediately before and after Low Field Magnetic Stimulation treatment on two separate days in a sham controlled, randomized trial, in order to assess the physiologic effects of Low Field Magnetic Stimulation on brain function in a geriatric population with bipolar depression.

Condition or Disease Intervention/Treatment Phase
  • Device: Low Field Magnetic Stimulation
N/A

Detailed Description

In this study, the investigators will examine changes in brain activity from Low Field Magnetic Stimulation in subjects over the age of 50 with bipolar disorder who are currently depressed using functional Magnetic Resonance Imaging and proton Magnetic Resonance Spectroscopy. Following screening visits, study procedures include two visits, at least two weeks apart, during which subjects will complete brief mood scales, undergo 15 minutes of imaging, receive 20 minutes of Low Field Magnetic Stimulation treatment, and then return to the scanner to undergo another 15 minutes of imaging procedures. Due to the crossover design, subjects receiving active treatment during the first visit will receive sham treatment during the second visit; subjects receiving sham treatment during the first visit will receive active treatment during the second visit. A follow-up phone call will occur two days after each imaging/treatment visit. The main endpoint of this study is the observation of changes in resting state functional Magnetic Resonance Imaging activity in post-treatment acquisitions as compared to pre-treatment acquisitions.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
This is a sham controlled, randomized, double blinded crossover design study of immediate change to brain activity caused by Low Field Magnetic Stimulation.This is a sham controlled, randomized, double blinded crossover design study of immediate change to brain activity caused by Low Field Magnetic Stimulation.
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
The device is operated using subject-specific links on a laptop. The active or sham identity of the links is prepared automatically and not known to study staff or participants.
Primary Purpose:
Basic Science
Official Title:
Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression
Actual Study Start Date :
May 29, 2018
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: Active first

Subjects receive active Low Field Magnetic Stimulation in the first imaging visit and sham in the second.

Device: Low Field Magnetic Stimulation
Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.

Other: Sham first

Subjects receive sham Low Field Magnetic Stimulation in the first imaging visit and active in the second.

Device: Low Field Magnetic Stimulation
Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.

Outcome Measures

Primary Outcome Measures

  1. Change in resting state brain activity measured by functional Magnetic Resonance Imaging. [Resting state functional Magnetic Resonance Imaging data are acquired 4 times, twice within one hour during imaging visit 1 and twice within one hour during imaging visit 2 which occurs at least two weeks later.]

    Comparison of change in brain activity occurring over the time of treatment, compared between active and sham treatment visits. This is assessed by combining pre and post treatment measures made during active and sham treatment visits using the following formula: (post active treatment - pre active treatment) - ( post sham - pre sham). The brain activity is measured using blood oxygenation level dependent image of brain activity acquired in the resting state using functional Magnetic Resonance Imaging.

Secondary Outcome Measures

  1. Change in resting state Gamma-aminobutyric acid concentration measured by Magnetic Resonance Spectroscopy. [Resting state Magnetic Resonance Spectroscopic data are acquired 4 times, twice within one hour during imaging visit 1 and twice within one hour during imaging visit 2 which occurs at least two weeks later.]

    Comparison of change in gamma-aminobutyric acid concentration in a region of the dorsal anterior cingulate cortex over the time of treatment, compared between active and sham treatment visits. This is assessed by combining pre and post treatment measures made during active and sham treatment visits using the following formula: (post active treatment - pre active treatment) - (post sham - pre sham)

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Subjects will have a diagnosis of Bipolar Disorder Type I or II, current episode depressed as measure by a MADRS ≥ 20.

  2. Subjects must be maintained on a stable dose of all psychotropic medications for a period of at least two weeks prior to screening.

  3. Subjects must be capable of providing informed consent.

  4. Subjects must permanently reside within a 2-hour drive of McLean Hospital.

  5. Subjects must be currently seen by a provider (psychiatrist, therapist, PCP) whose practice is within a 2-hour drive of McLean Hospital.

Exclusion Criteria:
  1. Dangerous or active suicidal ideation, as measured by the C-SSRS (see "Safety Measures" section), and physician evaluation.

  2. Subjects meeting DSM-5 criteria for any Axis I disorder other than Bipolar Disorder or an anxiety disorder (e.g. Major Depressive Disorder, dementia).

  3. Current mania as defined by a score of ≥ 10 on the Young Mania Rating Scale at screening.

  4. Subject has an MMSE score ≤ 24.

  5. Subject is pregnant or plans on becoming pregnant.

  6. Subject has recent history (within 7 days of screening) of ECT or TMS treatment.

  7. Subject has recent history of substance abuse (cannot meet DSM-5 criteria for substance abuse, no significant drug abuse within last 3 months, no history of dependence in last year, no drug use within last month, other than marijuana use).

  8. Subject has any contraindication for MRI (i.e. Presence of a pacemaker, neurostimulator, or metal in head or neck).

Contacts and Locations

Locations

Site City State Country Postal Code
1 McLean Hospital Belmont Massachusetts United States 02478

Sponsors and Collaborators

  • Mclean Hospital

Investigators

  • Principal Investigator: Brent P Forester, MD, Mclean Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Brent Forester, Chief, Division of Geriatric Psychiatry, Mclean Hospital
ClinicalTrials.gov Identifier:
NCT03484494
Other Study ID Numbers:
  • 2017P002783
First Posted:
Mar 30, 2018
Last Update Posted:
Aug 24, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Brent Forester, Chief, Division of Geriatric Psychiatry, Mclean Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 24, 2022